Real-world effectiveness of systemic agents approved for advanced non-small cell lung cancer: A SEER-medicare analysis

Medicine and Dentistry

• Patient 100%
• Analysis 100%
• Medicare 100%
• Surveillance, Epidemiology, and End Results 100%
• Non Small Cell Lung Cancer 100%
• Survival 42%
• Therapeutic Procedure 28%
• Chemotherapeutic Agent 28%
• Docetaxel 28%
• Drug 28%
• Pemetrexed 28%
• Bevacizumab 28%
• Lung Cancer 14%
• Association 14%
• Death 14%
• Oncology 14%
• Adjustment 14%
• Age 14%
• Survival Rate 14%
• Proportional Hazards Model 14%
• Hazard Ratio 14%
• Disparity 14%
• Male 14%
• Female 14%
• Patient Population 14%
• Platinum 14%
• Cancer Staging 14%
• Drug Therapy 14%
• Treatment of Non-Small Cell Lung Cancer 14%
• Cytotoxic Agent 14%
• Log Rank Test 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Non Small Cell Lung Cancer 100%
• Epidemiology 100%
• Survival 60%
• Drug 40%
• Docetaxel 40%
• Chemotherapy 40%
• Pemetrexed 40%
• Bevacizumab 40%
• Death 20%
• Lung Cancer 20%
• Platinum 20%
• Clinical Trial 20%
• Survival Rate 20%
• Cytotoxic Agent 20%
• Pharmaceutical Therapy 20%
• Cancer Staging 20%